SLS · SELLAS Life Sciences Group, Inc.
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with the $7.5 million in proceeds from warrant exercises subsequent to March 31, 2026, will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements, although the Company may pursue additional capital resources through public or private equity or debt financings or by entering into additional license agreements or collaborations with other companies.”View the 10-Q filed May 12, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
1,065,000 |
| 2026-01-07 | SCHEINBERG DAVID A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
50,000 |
| 2026-01-07 | Wasman Jane |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
50,000 |
| 2026-01-07 | CICIC DRAGAN |
SVP, Chief Development Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
300,000 |
| 2026-01-07 | Burns John Thomas |
CFO |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
300,000 |
| 2026-01-07 | Kalin Katherine Bach |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
50,000 |
| 2026-01-07 | VAN NOSTRAND ROBERT L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
50,000 |
| 2026-01-07 | Varian John |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
50,000 |
| 2025-12-03 | Burns John Thomas |
CFO |
Other↓
Filing footnotes — Common Stock (Direct)
Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. |
Common Stock
|
58,592 |
| 2025-12-03 | CICIC DRAGAN |
SVP, Chief Development Officer |
Other↓
Filing footnotes — Common Stock (Direct)
Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. |
Common Stock
|
63,800 |
| 2025-12-03 | Stergiou Angelos M. |
Director, President and CEO |
Other↓
Filing footnotes — Common Stock (Direct)
Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. |
Common Stock
|
187,066 |
| 2025-11-19 | Kalin Katherine Bach |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reflects the weighted average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $1.555 to $1.625 per share. Ms. Kalin undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price. |
Common Stock
|
63,400 |
| 2025-06-12 | VAN NOSTRAND ROBERT L |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2025-05-30 | Wasman Jane |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The shares were purchased in multiple transactions at a price of $1.69. The reporting person undertakes to provide SELLAS Life Sciences Group, Inc., any security holder of SELLAS Life Sciences Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at the price set forth in this footnote. |
Common Stock
|
20,000 |
| 2025-05-22 | Kalin Katherine Bach |
Director |
Buy↑
|
Common Stock
|
20,000 |
| 2025-01-10 | VAN NOSTRAND ROBERT L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
12,500 |
| 2025-01-10 | CICIC DRAGAN |
SVP, Chief Development Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Stock Option (Right to Buy)
|
169,500 |
| 2025-01-10 | Stergiou Angelos M. |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 257,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
257,000 |
| 2025-01-10 | Stergiou Angelos M. |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 243,900 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
243,900 |
| 2025-01-10 | Kalin Katherine Bach |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
18,500 |
| 2025-01-10 | Burns John Thomas |
CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Stock Option (Right to Buy)
|
169,500 |
| 2025-01-10 | Burns John Thomas |
CFO |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 113,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
113,000 |
| 2025-01-10 | SCHEINBERG DAVID A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
12,500 |
| 2025-01-10 | CICIC DRAGAN |
SVP, Chief Development Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 81,300 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
81,300 |
| 2025-01-10 | VAN NOSTRAND ROBERT L |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
18,500 |
| 2025-01-10 | Varian John |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
18,500 |
| 2025-01-10 | CICIC DRAGAN |
SVP, Chief Development Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 113,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
113,000 |
| 2025-01-10 | Kalin Katherine Bach |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
12,500 |
| 2025-01-10 | Wasman Jane |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
12,500 |
| 2025-01-10 | Burns John Thomas |
CFO |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 81,300 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
81,300 |
| 2025-01-10 | Stergiou Angelos M. |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Stock Option (Right to Buy)
|
385,750 |
| 2025-01-10 | Varian John |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
12,500 |
| 2025-01-10 | Wasman Jane |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
18,500 |
| 2025-01-10 | SCHEINBERG DAVID A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
18,500 |
| 2024-12-04 | Stergiou Angelos M. |
Director, President and CEO |
Other↓
Filing footnotes — Common Stock (Direct)
Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. |
Common Stock
|
28,289 |
| 2024-12-04 | CICIC DRAGAN |
SVP, Chief Development Officer |
Other↓
Filing footnotes — Common Stock (Direct)
Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. |
Common Stock
|
8,256 |
| 2024-12-04 | Burns John Thomas |
CFO |
Other↓
Filing footnotes — Common Stock (Direct)
Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. |
Common Stock
|
7,165 |
| 2024-01-22 | Stergiou Angelos M. |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Stock Option (Right to Buy)
|
238,500 |
| 2024-01-22 | SCHEINBERG DAVID A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
10,000 |
| 2024-01-22 | VAN NOSTRAND ROBERT L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
6,000 |
| 2024-01-22 | WOOD BARBARA A |
EVP, Gen. Counsel, Corp. Sec. |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 35,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
35,000 |
| 2024-01-22 | Kalin Katherine Bach |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
6,000 |
| 2024-01-22 | Francomano Robert |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Common Stock
|
20,000 |
| 2024-01-22 | VAN NOSTRAND ROBERT L |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
10,000 |
| 2024-01-22 | Francomano Robert |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Stock Option (Right to Buy)
|
30,000 |
| 2024-01-22 | Wasman Jane |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
6,000 |
| 2024-01-22 | Wasman Jane |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
10,000 |
| 2024-01-22 | Kalin Katherine Bach |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Stock Option (Right to Buy)
|
10,000 |
| 2024-01-22 | SCHEINBERG DAVID A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Common Stock
|
6,000 |
| 2024-01-22 | WOOD BARBARA A |
EVP, Gen. Counsel, Corp. Sec. |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Stock Option (Right to Buy)
|
50,000 |